Bharat Serums and Vaccines Limited (BSV), a leader in snake antivenom for over two decades, is ramping up efforts to address the rising incidence of snakebites as the monsoon season begins. With a strong focus on the 4A’s—Awareness, Accessibility, Availability, and Action—BSV is ensuring that the right treatment reaches victims at the right time.
Sivani Sarma Deka, COO of India Business at BSV, emphasized the company’s commitment to multi-sectoral collaborations and community education to dispel myths surrounding snakebite management. “We aim to ensure that every victim has access to timely and effective treatment,” she said. The company is also focused on providing continuous medical education to healthcare professionals in line with government guidelines for managing snakebite envenomation.
The government’s move to declare snakebites a “notifiable disease” is expected to improve data collection, resource allocation, and treatment access, which is crucial for reducing snakebite-related mortality. Hospitals are focusing on improving their snakebite management capabilities, ensuring that antivenom is readily available and healthcare personnel are well-trained to respond to emergencies swiftly.
